Celgene Corp. HALTS Tanzisertib and 3 Fresh Stock Analyses
Apple Inc. (NASDAQ:AAPL): Because the Piper Jaffray predicts that Apple shares will advance over the next month due to anticipation concerning the company’s new products, the firm recommends owning shares of the company into its Q3 results tomorrow. Piper believes that Apple iPhone sales for Q3 will beat buy side expectations, and the firm keeps its Overweight rating on the shares.
Don’t Miss: Apple vs. Samsung RAGES ON!
The Blackstone Group (NYSE:BX) is believed by Argus to have “tremendous” earnings power which can be unlocked by the company in the future, and the firm keeps the stock on its Focus List. The firm maintains its Buy rating but drops its price target on the shares from $18 to $16.
FTI Consulting, Inc. (NYSE:FCN) was added to Deutsche Bank’s short-term buy list.
Celgene Corporation (NASDAQ:CELG) confirmed that it has discontinued tanzisertib, an early stage antifibrotic/antiinflammatory drug in early development, development because of toxicities, states Wells Fargo. The firm does not believe the discontinuation will be material to shares, and it maintains its Outperform rating on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.